Extended-Release vs Sublingual Buprenorphine in Pregnancy Through 12 Months Post Partum: A Randomized Clinical Trial - PubMed
5 hours ago
- #Buprenorphine
- #Opioid Use Disorder
- #Pregnancy
- The study compared extended-release (ER) buprenorphine with sublingual buprenorphine for treating opioid use disorder (OUD) in pregnancy through 12 months postpartum.
- ER buprenorphine showed higher illicit opioid abstinence rates during pregnancy (82.5% vs. 72.6%) compared to sublingual buprenorphine.
- Postpartum abstinence rates declined and were similar between both groups (60.2% vs. 59.5%).
- Participants on ER buprenorphine experienced fewer serious adverse events during pregnancy (8.7% vs. 26.8%) and postpartum (6.0% vs. 18.6%).
- Infants exposed to ER buprenorphine did not differ significantly in need for opioid treatment for neonatal opioid withdrawal syndrome (NOWS) compared to sublingual-exposed infants.
- ER-exposed neonates had larger head circumferences at birth compared to sublingual-exposed neonates (34.0 cm vs. 33.4 cm).
- The study supports the use of weekly ER buprenorphine for OUD treatment during pregnancy.